BBLG
Bone Biologics Corp
NASDAQ: BBLG · HEALTHCARE · BIOTECHNOLOGY
$0.39
-0.51% today
Updated 2026-10-29
Market cap
$1.13M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.37
Dividend yield
—
52W range
$0 – $3
Volume
0.1M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.8
Quality
C+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-14.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$12.20
+3028.21%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -14.31 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-518440.00
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-1.48M | $-8.95M | $-4.11M | $-3.11M | $-773702.00 |
| EPS | — | — | — | — | $-1.37 |
| Free cash flow | $-3.57M | $-9.56M | $-4.12M | $-2.69M | $-518440.00 |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Bone Biologics Corp trades at $0.39. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -14.31, it sits in the distress.
Frequently asked questions
What is Bone Biologics Corp's stock price?
Bone Biologics Corp (BBLG) trades at $0.39.
Is Bone Biologics Corp overvalued?
Bone Biologics Corp carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Bone Biologics Corp (BBLG)?
The 12-month analyst consensus target is $12.20, about 3028.2% above the current $0.39. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Bone Biologics Corp's Altman Z-Score is -14.31, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-61.20%
Beta0.57
50D MA$0.55
200D MA$1.12
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—